Stock comparison
Halozyme Therapeutics
Nektar Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
NKTR
Nektar Therapeutics
Market cap
$1.3B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | NKTR | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 37D | HALO |
| Benjamin Graham | 83A | 56D | HALO |
| Philip Fisher | 65B | 48D | HALO |
| Peter Lynch | 53D | 3F | HALO |
| Joel Greenblatt | 40D | 2F | HALO |
| Charlie Munger | 80C | 39D | HALO |
| Terry Smith | 84A | 43D | HALO |
Side-by-side metrics
| Metric | HALO | NKTR |
|---|---|---|
| Market cap | $8.1B | $1.3B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | - |
| ROIC (TTM) | 23.65% | -17.17% |
| Gross margin | 81.24% | 99.38% |
| Net margin | 23.13% | -2.84% |
| Revenue CAGR 5y | 33.23% | -14.2% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- ROIC (TTM)23.65%vs -17.17%+173%
- Revenue CAGR 5y33.23%vs -14.2%+143%
- Net margin23.13%vs -2.84%+108%
- Market cap$8.1Bvs $1.3B+84%
NKTR leads on
- EV/EBIT-vs 10.2x+192%
- P/E (TTM)-vs 24.0x+151%
- Debt / Equity0.1xvs 1.0x+85%
- Gross margin99.38%vs 81.24%+18%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.